Secondary efficacy analyses of the pivotal SEQUOIA-HCM trial continued to favor aficamten, supporting a potential role for another cardiac myosin inhibitor in obstructive hypertrophic cardiomyopathy ...

The novel cardiac myosin inhibitor aficamten improved peak oxygen uptake in symptomatic obstructive hypertrophic cardiomyopathy (HCM), the pivotal SEQUOIA-HCM trial showed. At 24 weeks, the mean ...

Please provide your email address to receive an email when new articles are posted on . Cardiac myosin inhibitors are now recommended as therapy for certain patients with obstructive hypertrophic ...

The American Heart Association (AHA) and the American College of Cardiology (ACC), with the support of several other professional societies, have released updated guidelines for the management of ...

Hypertrophic cardiomyopathy (HCM) is the most common inherited form of heart disease, associated with over 1,000 mutations, many in β-cardiac myosin (MYH7). Molecular studies of myosin with different ...

A human heart might contract some three billion times over a lifetime, and each one of those contractions is driven by a protein called myosin. One of three classes of so-called motor proteins in our ...

A decade ago, when Courtney Miller of Scripps Research in Florida found that blocking a specific protein can interrupt methamphetamine addiction in mice, it was difficult to imagine drugs targeting ...